Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Other Announcement

Gujarat Themis Biosyn Ltd filed its quarterly Shareholding Pattern for the period ended June 30, 2026, in compliance with Regulation 31 of SEBI LODR.

Gujarat Themis Biosyn Annual General Meeting

Gujarat Themis Biosyn Limited issued a postal ballot notice seeking shareholder approval to raise funds up to ₹1,000 Crore via Qualified Institutions Placement (QIP).

Gujarat Themis Biosyn Other Announcement

Gujarat Themis Biosyn Ltd submitted its quarterly shareholding pattern for the period ending June 30, 2026, noting inter-se promoter group share transfers.

Gujarat Themis Biosyn Credit Rating

CARE Ratings has placed Gujarat Themis Biosyn's bank facilities on 'Rating Watch with Negative Implications' following announced large-scale acquisitions.

Gujarat Themis Biosyn Credit Rating

CARE Ratings placed Gujarat Themis Biosyn's ₹80 Crore bank facilities on 'Rating Watch with Negative Implications'. This follows the company's announcement of major international acquisitions.

Value

₹80.00 Cr

Gujarat Themis Biosyn Promoter Buying (Off-Market): ₹20 Cr

Promoter Sachin D. Patel proposes to acquire up to 0.50% stake in Gujarat Themis Biosyn. The Rs.20 Crore inter-se transfer increases his holding to 2.77%.

Value

₹20.00 Cr

Execution

21.07.2026 to 31.07.2026

Gujarat Themis Biosyn Legal & Regulatory

Gujarat Themis Biosyn initiated arbitration against Optimus Drugs claiming Rs. 90.24 Crore. The dispute involves breached 'Take-or-Pay' obligations and terminated supply agreements.

Value

₹90.24 Cr

Gujarat Themis Biosyn Legal & Regulatory

Gujarat Themis Biosyn amicably settled its commercial dispute with Optimus Drugs Private Limited. The arbitration disposal results in no material financial impact or penalties.

Gujarat Themis Biosyn Fund Raise

Shareholders approved a special resolution to raise funds via a Qualified Institutions Placement. The approval enables the company to issue new equity shares.

Gujarat Themis Biosyn Annual General Meeting

Gujarat Themis Biosyn announced shareholders approved fund raising via Qualified Institutions Placement. The special resolution passed with 99.97% majority through a postal ballot process.

Gujarat Themis Biosyn Promoter Buying (Off-Market): ₹20 Cr

Promoter Sachin D. Patel will acquire up to 5.25 lakh shares worth Rs.20 Cr from Pharmaceutical Business Group (India) Ltd. His stake rises from 2.29% to 2.77%.

Value

₹20.00 Cr

Execution

08 July 2026 to 14 July 2026

Gujarat Themis Biosyn Share Pledge

CTL Trusteeship Ltd filed a SAST Reg 29(1) disclosure on encumbrances over PBGIL shares. This creates an indirect encumbrance over Gujarat Themis Biosyn Ltd shares.

Gujarat Themis Biosyn Promoter Buying (Off-Market)

Gujarat Themis Biosyn Ltd reported a transfer of 24.97 lac shares to promoter Sachin D. Patel, raising his stake to 2.29%. The deal is an off‑market promoter acquisition.

Gujarat Themis Biosyn Earnings Call: Key Takeaways

GTBL is transforming into a global CDMO platform via acquisitions of MicroBiopharm Japan and Sanofi's anti-TB portfolio. FY26 revenue stood at INR 16,582 Lakhs with a 45.55% EBITDA margin.

Gujarat Themis Biosyn Legal & Regulatory

Gujarat Themis Biosyn initiated arbitration against Optimus Drugs claiming ₹90.24 Crore. The dispute follows a supply agreement termination and breach of take-or-pay obligations.

Value

₹90.24 Cr

Gujarat Themis Biosyn Legal & Regulatory

Gujarat Themis Biosyn faces an arbitration claim of ₹113.80 Crore from Optimus Drugs. The company expects no financial implication from this litigation.

Value

₹115.0 Cr

Gujarat Themis Biosyn Results Correction

Gujarat Themis Biosyn Limited submitted a corrected XBRL filing. This corrects the omission of Earnings Per Share from previous results.

Gujarat Themis Biosyn Promoter Buying (Off-Market): ₹100 Cr

Gujarat Themis Biosyn Ltd promoter Sachin Patel proposes to acquire up to 2.6 million shares worth ₹100 Crore. The stake will rise to about 2.38% post‑transfer.

Value

₹100.0 Cr

Gujarat Themis Biosyn Annual General Meeting

Gujarat Themis Biosyn Limited has issued a postal ballot notice to seek shareholder approval for a Rs. 1,000 Crore QIP. The move aims to fund growth and strategic projects.

Value

₹1,000 Cr

Gujarat Themis Biosyn Fund Raise of ₹1,000 Cr

Gujarat Themis Biosyn's board approved raising ₹1,000 Crore through a Qualified Institutions Placement. The company also plans a preferential issue of equity shares to non-promoters.

Value

₹1,000 Cr

Gujarat Themis Biosyn Annual General Meeting

Gujarat Themis Biosyn announced the approval of special resolutions via postal ballot. Shareholders passed resolutions to increase borrowing limits and loan/investment capacities with requisite majorities.

Gujarat Themis Biosyn Board Meeting Date

Gujarat Themis Biosyn scheduled a board meeting for June 6, 2026. Directors will evaluate fund-raising options including QIP or preferential allotment to strengthen the capital base.

Gujarat Themis Biosyn Merger & Restructuring Worth ₹1.11 Cr

Gujarat Themis Biosyn incorporated a wholly owned pharmaceutical subsidiary in Ireland with €1,00,000 capital. The move marks an international expansion into European markets.

Value

₹1.11 Cr

Gujarat Themis Biosyn Other Announcement

Gujarat Themis Biosyn Ltd submitted its Annual Secretarial Compliance Report for FY2024-25. The report confirms overall regulatory adherence with minor historical compliance observations noted.

Gujarat Themis Biosyn Earnings Call: Key Takeaways

Gujarat Themis Biosyn Limited reports Q4 FY26 revenue of ₹44.23 cr (+17.2% YoY) and PAT of ₹10.89 cr. Management announced two major inorganic acquisitions to pivot towards a CDMO model.

Gujarat Themis Biosyn Q4 FY26 Results: Net Profit ₹10.9 Cr, Down 9.2% YoY

Gujarat Themis Biosyn Ltd reported revenue from operations of ₹44.2 Cr (+17.2% YoY) and net profit of ₹10.9 Cr (-9.2% YoY) for Q4 FY26.

Key figure

Net profit ₹10.9 Cr · -9.2% YoY

Gujarat Themis Biosyn Financial Results

Gujarat Themis Biosyn approved FY26 financial results and recommended a ₹7.30 Crore final dividend. The Board also proposed a preferential equity issue to non-promoters.

Value

₹7.30 Cr

Gujarat Themis Biosyn Acquisition Worth ₹1,300 Cr

Gujarat Themis Biosyn is acquiring MicroBiopharm Japan for ₹1,300 Crore to expand its CDMO capabilities. This strategic move strengthens its position in precision fermentation and biotechnology.

Value

₹1,300 Cr

Execution

30/09/2026

Gujarat Themis Biosyn Earnings Call: Key Takeaways

Gujarat Themis Biosyn (GTBL) announced the acquisition of 100% of MicroBiopharm Japan (MBJ) for JPY 21.5 Bn (~INR 1,300 Cr), transitioning GTBL into a globally integrated fermentation-based CDMO.

Gujarat Themis Biosyn Acquisition Worth ₹1,290 Cr

Gujarat Themis Biosyn Limited will acquire 100% of Japan-based MicroBiopharm Japan for ₹1,290 Crore. This strategic acquisition expands GTBL's CDMO capabilities into advanced precision fermentation.

Value

₹1,290 Cr

Execution

Q2 FY2027